RST 001

Drug Profile

RST 001

Alternative Names: RST-001

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wayne State University
  • Developer RetroSense Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Retinitis pigmentosa

Most Recent Events

  • 06 Sep 2016 Allergan acquires RST 001 from RetroSense Therapeutics
  • 30 Aug 2016 RetroSense Therapeutics has patent protection for the methods of restoring or improving vision using optogenetic approaches in USA
  • 01 Nov 2015 Phase-I/II clinical trials in Retinitis pigmentosa in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top